FDA awards Regenerative Medicine Advanced Therapy Designation to CAN-2409 for prostate cancer
Intraprostatic drug elution therapy shows promise for BPH-related LUTS
Subcutaneous nivolumab approved in EU, Canada for solid tumors
Phase 3 trial of tebipenem HBr for cUTI stopped early for efficacy
